Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Jourdan

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Haematologica|June 7, 2007
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell linesJérôme Moreaux, Dirk Hose, Michel Jourdan, et al.
Theranostics|February 28, 2019
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistanceVeronika Vikova, Michel Jourdan, Nicolas Robert, et al.
Immunological Reviews|April 21, 2006
Microarray-based understanding of normal and malignant plasma cellsJohn De Vos, Dirk Hose, Thierry Rème, et al.
Haematologica|December 22, 2010
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesJérôme Moreaux, Bernard Klein, Régis Bataille, et al.
European Journal of Haematology|May 22, 2009
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loopJérôme Moreaux, Anne-Catherine Sprynski, Stacey R Dillon, et al.
Oncotarget|April 9, 2016
Differential effects of lenalidomide during plasma cell differentiationMichel Jourdan, Maïlys Cren, Peter Schafer, et al.
Oncogene|October 3, 2002
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arraysJohn De Vos, Thomas Thykjaer, Karin Tarte, et al.
British Journal of Haematology|June 5, 2007
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growthMichel Jourdan, Jérôme Moreaux, John De Vos, et al.
Haematologica|July 11, 2019
Kinome expression profiling to target new therapeutic avenues in multiple myelomaHugues de Boussac, Angélique Bruyer, Michel Jourdan, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Haematologica|June 7, 2007
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell linesJérôme Moreaux, Dirk Hose, Michel Jourdan, et al.
Theranostics|February 28, 2019
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistanceVeronika Vikova, Michel Jourdan, Nicolas Robert, et al.
Immunological Reviews|April 21, 2006
Microarray-based understanding of normal and malignant plasma cellsJohn De Vos, Dirk Hose, Thierry Rème, et al.
Haematologica|December 22, 2010
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesJérôme Moreaux, Bernard Klein, Régis Bataille, et al.
European Journal of Haematology|May 22, 2009
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loopJérôme Moreaux, Anne-Catherine Sprynski, Stacey R Dillon, et al.
Oncotarget|April 9, 2016
Differential effects of lenalidomide during plasma cell differentiationMichel Jourdan, Maïlys Cren, Peter Schafer, et al.
Oncogene|October 3, 2002
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arraysJohn De Vos, Thomas Thykjaer, Karin Tarte, et al.
British Journal of Haematology|June 5, 2007
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growthMichel Jourdan, Jérôme Moreaux, John De Vos, et al.
Haematologica|July 11, 2019
Kinome expression profiling to target new therapeutic avenues in multiple myelomaHugues de Boussac, Angélique Bruyer, Michel Jourdan, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Pageof 4